|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PELI2 |
Gene summary for PELI2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PELI2 | Gene ID | 57161 |
| Gene name | pellino E3 ubiquitin protein ligase family member 2 | |
| Gene Alias | PELI2 | |
| Cytomap | 14q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q9H716 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57161 | PELI2 | CCI_1 | Human | Cervix | CC | 1.63e-13 | 9.06e-01 | 0.528 |
| 57161 | PELI2 | CCI_2 | Human | Cervix | CC | 3.07e-08 | 1.17e+00 | 0.5249 |
| 57161 | PELI2 | CCI_3 | Human | Cervix | CC | 9.89e-06 | 4.16e-01 | 0.516 |
| 57161 | PELI2 | AEH-subject1 | Human | Endometrium | AEH | 5.13e-04 | 2.41e-01 | -0.3059 |
| 57161 | PELI2 | AEH-subject4 | Human | Endometrium | AEH | 5.31e-08 | 3.99e-01 | -0.2657 |
| 57161 | PELI2 | AEH-subject5 | Human | Endometrium | AEH | 3.09e-15 | 5.81e-01 | -0.2953 |
| 57161 | PELI2 | EEC-subject1 | Human | Endometrium | EEC | 2.08e-02 | 2.58e-01 | -0.2682 |
| 57161 | PELI2 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 3.29e-02 | -7.54e-02 | -0.1934 |
| 57161 | PELI2 | LZE24T | Human | Esophagus | ESCC | 3.33e-16 | 4.30e-01 | 0.0596 |
| 57161 | PELI2 | P2T-E | Human | Esophagus | ESCC | 1.83e-08 | 1.79e-01 | 0.1177 |
| 57161 | PELI2 | P8T-E | Human | Esophagus | ESCC | 6.82e-11 | 2.10e-01 | 0.0889 |
| 57161 | PELI2 | P9T-E | Human | Esophagus | ESCC | 1.86e-06 | 1.91e-01 | 0.1131 |
| 57161 | PELI2 | P10T-E | Human | Esophagus | ESCC | 6.02e-25 | 3.86e-01 | 0.116 |
| 57161 | PELI2 | P12T-E | Human | Esophagus | ESCC | 4.80e-26 | 5.43e-01 | 0.1122 |
| 57161 | PELI2 | P15T-E | Human | Esophagus | ESCC | 2.02e-29 | 6.55e-01 | 0.1149 |
| 57161 | PELI2 | P16T-E | Human | Esophagus | ESCC | 4.46e-05 | 1.31e-01 | 0.1153 |
| 57161 | PELI2 | P22T-E | Human | Esophagus | ESCC | 1.39e-09 | 9.72e-02 | 0.1236 |
| 57161 | PELI2 | P23T-E | Human | Esophagus | ESCC | 2.30e-04 | 1.35e-01 | 0.108 |
| 57161 | PELI2 | P26T-E | Human | Esophagus | ESCC | 1.21e-44 | 6.73e-01 | 0.1276 |
| 57161 | PELI2 | P27T-E | Human | Esophagus | ESCC | 1.09e-12 | 1.63e-01 | 0.1055 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00431226 | Lung | IAC | regulation of I-kappaB kinase/NF-kappaB signaling | 51/2061 | 249/18723 | 8.41e-06 | 2.87e-04 | 51 |
| GO:00002096 | Lung | IAC | protein polyubiquitination | 49/2061 | 236/18723 | 8.51e-06 | 2.89e-04 | 49 |
| GO:00431235 | Lung | IAC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 38/2061 | 186/18723 | 1.19e-04 | 2.25e-03 | 38 |
| GO:00434103 | Lung | IAC | positive regulation of MAPK cascade | 78/2061 | 480/18723 | 2.72e-04 | 4.50e-03 | 78 |
| GO:000020912 | Lung | AIS | protein polyubiquitination | 49/1849 | 236/18723 | 3.85e-07 | 3.16e-05 | 49 |
| GO:00434101 | Lung | AIS | positive regulation of MAPK cascade | 72/1849 | 480/18723 | 2.11e-04 | 4.32e-03 | 72 |
| GO:004312213 | Lung | AIS | regulation of I-kappaB kinase/NF-kappaB signaling | 41/1849 | 249/18723 | 7.57e-04 | 1.08e-02 | 41 |
| GO:000724913 | Lung | AIS | I-kappaB kinase/NF-kappaB signaling | 45/1849 | 281/18723 | 7.90e-04 | 1.11e-02 | 45 |
| GO:000724922 | Lung | AAH | I-kappaB kinase/NF-kappaB signaling | 21/613 | 281/18723 | 4.01e-04 | 1.78e-02 | 21 |
| GO:004312222 | Lung | AAH | regulation of I-kappaB kinase/NF-kappaB signaling | 19/613 | 249/18723 | 5.79e-04 | 2.23e-02 | 19 |
| GO:00434102 | Lung | AAH | positive regulation of MAPK cascade | 28/613 | 480/18723 | 2.42e-03 | 4.98e-02 | 28 |
| GO:000020918 | Skin | AK | protein polyubiquitination | 41/1910 | 236/18723 | 4.78e-04 | 4.44e-03 | 41 |
| GO:004312224 | Skin | AK | regulation of I-kappaB kinase/NF-kappaB signaling | 42/1910 | 249/18723 | 7.65e-04 | 6.39e-03 | 42 |
| GO:000724920 | Skin | AK | I-kappaB kinase/NF-kappaB signaling | 46/1910 | 281/18723 | 8.56e-04 | 7.08e-03 | 46 |
| GO:004312319 | Skin | AK | positive regulation of I-kappaB kinase/NF-kappaB signaling | 31/1910 | 186/18723 | 4.21e-03 | 2.46e-02 | 31 |
| GO:00434108 | Skin | AK | positive regulation of MAPK cascade | 66/1910 | 480/18723 | 7.41e-03 | 3.78e-02 | 66 |
| GO:004341014 | Skin | SCCIS | positive regulation of MAPK cascade | 42/919 | 480/18723 | 2.15e-04 | 4.02e-03 | 42 |
| GO:0043122111 | Skin | SCCIS | regulation of I-kappaB kinase/NF-kappaB signaling | 24/919 | 249/18723 | 1.28e-03 | 1.49e-02 | 24 |
| GO:0007249110 | Skin | SCCIS | I-kappaB kinase/NF-kappaB signaling | 26/919 | 281/18723 | 1.49e-03 | 1.68e-02 | 26 |
| GO:000020919 | Skin | SCCIS | protein polyubiquitination | 22/919 | 236/18723 | 3.03e-03 | 2.76e-02 | 22 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PELI2 | SNV | Missense_Mutation | rs749388627 | c.686N>A | p.Arg229Gln | p.R229Q | Q9HAT8 | protein_coding | deleterious(0.05) | possibly_damaging(0.582) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| PELI2 | SNV | Missense_Mutation | novel | c.416T>A | p.Phe139Tyr | p.F139Y | Q9HAT8 | protein_coding | tolerated(0.39) | benign(0.019) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| PELI2 | SNV | Missense_Mutation | rs200311934 | c.974G>A | p.Arg325Gln | p.R325Q | Q9HAT8 | protein_coding | tolerated(0.24) | possibly_damaging(0.598) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
| PELI2 | SNV | Missense_Mutation | c.801N>C | p.Gln267His | p.Q267H | Q9HAT8 | protein_coding | tolerated(0.51) | possibly_damaging(0.77) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PELI2 | SNV | Missense_Mutation | c.841C>T | p.Arg281Trp | p.R281W | Q9HAT8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A24S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD | |
| PELI2 | SNV | Missense_Mutation | rs557894615 | c.601N>A | p.Glu201Lys | p.E201K | Q9HAT8 | protein_coding | tolerated(0.44) | benign(0.146) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| PELI2 | insertion | Frame_Shift_Ins | novel | c.978_979insATCTTCAAATATTTTTTTGCTTGTTCTGAGAGGAAAGAATCTTGGA | p.Asp327IlefsTer41 | p.D327Ifs*41 | Q9HAT8 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| PELI2 | SNV | Missense_Mutation | novel | c.1187C>G | p.Ala396Gly | p.A396G | Q9HAT8 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| PELI2 | SNV | Missense_Mutation | c.275N>G | p.Glu92Gly | p.E92G | Q9HAT8 | protein_coding | deleterious(0.02) | probably_damaging(0.922) | TCGA-EA-A3HQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| PELI2 | SNV | Missense_Mutation | rs375391259 | c.616N>A | p.Gly206Arg | p.G206R | Q9HAT8 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-JW-A852-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |